This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Diffuse large B-cell lymphoma.
Journal

Diffuse large B-cell lymphoma.

Read time: 1 mins
Published:1st Oct 2008
Author: Friedberg JW, Fisher RI.
Availability: Free full text
Ref.:Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix.
DOI:10.1016/j.hoc.2008.07.002.

Diffuse large B-cell lymphoma (DLBCL) remains a curable lymphoma, with improved outcome resulting in large part from the incorporation of rituximab in standard regimens. The disease is heterogeneous clinically, morphologically, and molecularly. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy with rituximab remains a standard therapeutic approach for most patients who have DLBCL, it is anticipated that novel agents will be included in treatment regimens for many patients in the near future.

 

Read abstract on library site

Access full article